| Business

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

J&J wins U.S. approval for TB tablet

Email Newsletters

Sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

JNJ $70.10 +$0.62

at close on MONDAY

By Anna Edney C.2012 Bloomberg News
Monday, Dec. 31, 2012, 10:30 p.m.

Johnson & Johnson won regulatory approval for its tuberculosis tablet Sirturo, the first drug in 40 years that provides a new way to treat the contagious lung infection.

The Food and Drug Administration cleared Sirturo to be added to therapies for use by adults whose illness is resistant to multiple medicines, the New Brunswick, N.J.- based company said Monday.

While tuberculosis was once the leading cause of death in the nation, the drug-resistant version of the illness affected about 98 people last year, according to the Centers for Disease Control and Prevention.

Subscribe today! Click here for our subscription offers.



Show commenting policy

Most-Read Business Headlines

  1. Pennsylvania Game Commission reaps revenue from shale gas under game lands
  2. University of Pittsburgh researchers revisit war of electric currents
  3. Energy Spotlight: Minking Chyu
  4. Batteries key to alternative energy’s success
  5. As historic breakup nears, Alcoa works to redefine its ‘advantage’
  6. Signs of steady U.S. economy: Pay, home sales up, unemployment applications down
  7. Make green home upgrades pay off
  8. Paying pals digitally catches on
  9. Nutritional supplement makers, led by GNC, want to create voluntary safety standards
  10. Fuel cell standoff slows car technology’s rise in popularity
  11. Western Pa. conference aims to connect veterans with businesses with contracting experts, specialists